Over 9000 Thousand!

Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis

15 May 2025

Roche announced today that the FDA has approved the VENTANA® MET (SP44) RxDx Assay, the first companion diagnostic approved to aid in determining MET (also known as c-Met) protein expression in NSQ-NSCLC patients.

Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline

15 May 2025

Tempus AI, Inc. a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline.

Sanyou Bio and TransRecoBio Forge Strategic Alliance to Build a New Ecosystem for the Full Industry Chain

14 May 2025

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and TransRecoBio (Wenzhou) Biotechnology Co., Ltd. ("TransRecoBio") officially signed a strategic cooperation agreement.

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

13 May 2025

Beam Therapeutics Inc, a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy

Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

12 May 2025

Capsida Biotherapeutics today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-002, its wholly owned first-in-class, intravenously (IV)

Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale

9 May 2025

Peptone, a biotech company developing novel therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases, today announced a partnership with Evotec to accelerate and scale the creation of small molecule IDP-targeted

BioVaxys and Sona Nanotech Enter Research Collaboration

8 May 2025

BioVaxys Technology Corp. and Sona Nanotech Inc. announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy

Adcentrx Therapeutics Granted Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical Cancer

7 May 2025

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

6 May 2025

Rezolute, Inc, a late-stage rare disease company focused on treating hypoglycemia caused by HI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.

TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy

5 May 2025

In a groundbreaking advancement for precision oncology, TAE Life Sciences (TLS) today announced the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center

News